On July 31, Express Scripts identified new formulary exclusions that will go into effect on January 1, 2018. For example, Amgen’s rG-CSF product, NEUPOGEN, will be excluded in favor of Teva’s rG-CSF product, GRANIX, and Sandoz’s biosimilar, ZARXIO. Express Scripts has not explained, however, what the reimbursement level will be for GRANIX and ZARXIO, or how much a patient will have to pay for them as compared to the cost of NEUPOGEN.
Express Scripts noted that “[t]he full list of excluded products [for 2018] will be available on or before September 15, 2017.”
Stay tuned to Big Molecule Watch for further updates.
The post Neupogen Dropped in New Formulary Exclusions appeared first on Goodwin Procter BioSimilars Blog.